Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16134177rdf:typepubmed:Citationlld:pubmed
pubmed-article:16134177lifeskim:mentionsumls-concept:C1261473lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0086409lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0035168lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0076080lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:16134177lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:16134177pubmed:issue8lld:pubmed
pubmed-article:16134177pubmed:dateCreated2005-10-10lld:pubmed
pubmed-article:16134177pubmed:abstractTextThe objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma.lld:pubmed
pubmed-article:16134177pubmed:languageenglld:pubmed
pubmed-article:16134177pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134177pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16134177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16134177pubmed:statusMEDLINElld:pubmed
pubmed-article:16134177pubmed:monthOctlld:pubmed
pubmed-article:16134177pubmed:issn0008-543Xlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:BuesaJose MJMlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:MaurelJoanJlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:CasadoAntonio...lld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:MartinJavierJlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:Garcia del...lld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:BoverIsabelIlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:CruzJosefinaJlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:Lopez-PousaAn...lld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:Martinez-Truf...lld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:PovedaAndresAlld:pubmed
pubmed-article:16134177pubmed:authorpubmed-author:Spanish...lld:pubmed
pubmed-article:16134177pubmed:copyrightInfoCopyright 2005 American Cancer Societylld:pubmed
pubmed-article:16134177pubmed:issnTypePrintlld:pubmed
pubmed-article:16134177pubmed:day15lld:pubmed
pubmed-article:16134177pubmed:volume104lld:pubmed
pubmed-article:16134177pubmed:ownerNLMlld:pubmed
pubmed-article:16134177pubmed:authorsCompleteYlld:pubmed
pubmed-article:16134177pubmed:pagination1706-12lld:pubmed
pubmed-article:16134177pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:meshHeadingpubmed-meshheading:16134177...lld:pubmed
pubmed-article:16134177pubmed:year2005lld:pubmed
pubmed-article:16134177pubmed:articleTitleA phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.lld:pubmed
pubmed-article:16134177pubmed:affiliationDepartment of Medical Oncology, Institut Catala d'Oncologia, Institut d'Investigacio Bellvitge (IDIBELL), Barcelona, Spain. garciadelmuro@iconcologia.netlld:pubmed
pubmed-article:16134177pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16134177pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16134177pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16134177pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16134177pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16134177lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16134177lld:pubmed